These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4096874)

  • 41. Renal osteodystrophy--pathogenesis and treatment.
    Cushner HM; Adams ND
    Am J Med Sci; 1985 Dec; 290(6):234-45. PubMed ID: 3909812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of verapamil on bone resorption and formation in uremic rats.
    Chagnac A; Gazit D; Zahavi I; Sela J; Levi J
    Miner Electrolyte Metab; 1989; 15(5):291-4. PubMed ID: 2811787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review: Renal osteodystrophy--pathogenesis and treatment.
    Cushner HM; Adams ND
    Am J Med Sci; 1986 Apr; 291(4):264-75. PubMed ID: 3518448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
    Ghazali A; Fardellone P; Pruna A; Atik A; Achard JM; Oprisiu R; Brazier M; Remond A; Morinière P; Garabedian M; Eastwood J; Fournier A
    Kidney Int; 1999 Jun; 55(6):2169-77. PubMed ID: 10354266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved bone formation in dialysis patients after substitution of calcium carbonate for aluminum gels.
    Hercz G; Andress DL; Norris KC; Shinaberger JH; Slatopolsky EA; Sherrard DJ; Coburn JW
    Trans Assoc Am Physicians; 1987; 100():139-46. PubMed ID: 3455064
    [No Abstract]   [Full Text] [Related]  

  • 46. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome.
    Freundlich M; Jofe M; Goodman WG; Salusky IB
    Pediatr Nephrol; 2004 Apr; 19(4):400-7. PubMed ID: 14991389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease.
    Parisien M; Charhon SA; Arlot M; Mainetti E; Chavassieux P; Chapuy MC; Meunier PJ
    J Bone Miner Res; 1988 Jun; 3(3):259-67. PubMed ID: 3213621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aluminum osteopathy.
    Cournot-Witmer G
    Contrib Nephrol; 1984; 38():59-64. PubMed ID: 6713901
    [No Abstract]   [Full Text] [Related]  

  • 49. Haemodialysis related osteomalacia: a staining method to demonstrate aluminium.
    Buchanan MR; Ihle BU; Dunn CM
    J Clin Pathol; 1981 Dec; 34(12):1352-4. PubMed ID: 6173400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low rate of bone formation with or without histologic appearance of osteomalacia in patients with aluminum intoxication.
    Charhon SA; Chavassieux PM; Chapuy MC; Boivin GY; Meunier PJ
    J Lab Clin Med; 1985 Aug; 106(2):123-31. PubMed ID: 2410522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.
    Wang M; Hercz G; Sherrard DJ; Maloney NA; Segre GV; Pei Y
    Am J Kidney Dis; 1995 Nov; 26(5):836-44. PubMed ID: 7485142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The case for parathyroid hormone.
    Mayor GH
    Am J Kidney Dis; 1985 Nov; 6(5):306-8. PubMed ID: 3904422
    [No Abstract]   [Full Text] [Related]  

  • 53. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 54. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure.
    Dunstan CR; Evans RA; Hills E; Wong SY; Alfrey AC
    Calcif Tissue Int; 1984 Mar; 36(2):133-8. PubMed ID: 6430496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of long-term vitamin D2 treatment on bone morphometry and biochemical values in anticonvulsant osteomalacia.
    Mosekilde L; Melsen F; Christensen MS; Lund B; Sorenson OH
    Acta Med Scand; 1977; 201(4):303-7. PubMed ID: 300547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Practical considerations on aluminum hazards in uremic patients on dialysis].
    Gilli P; Malacarne F
    Minerva Nefrol; 1982; 29(4):233-4. PubMed ID: 7155444
    [No Abstract]   [Full Text] [Related]  

  • 58. Role of aluminum in uremic osteodystrophy.
    Luciani L; Rovelli E; Colleoni N; Mocetti P; Ballanti P; Bonucci E; D'Amico G
    Contrib Nephrol; 1990; 77():168-76. PubMed ID: 2188785
    [No Abstract]   [Full Text] [Related]  

  • 59. [Renal osteodystrophy: aluminium and secondary hyperparathyroidism].
    de Vernejoul MC
    Rev Prat; 1990 Mar; 40(7):613-8. PubMed ID: 2326587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Iatrogenic osteomalacia and myopathy due to phosphate depletion.
    Baker LR; Ackrill P; Cattell WR; Stamp TC; Watson L
    Br Med J; 1974 Jul; 3(5924):150-2. PubMed ID: 4843652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.